Skip to main content
SpringerLink
Log in

Alternative Clinical Indications of Botulinum Toxin

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Botulinum toxin type A (BoNTA) is a powerful neurotoxin that inhibits acetylcholine release from presynaptic vesicles. The potency and safety profile of BoNTA grant the toxin vast therapeutic potential. It has been used off-label for a variety of dermatologic conditions. This review aims to analyze published literature regarding the benefits and risks of the off-label use of BoNTA beyond facial lines, including eccrine hidrocystomas, enlarged pores, keloids and hypertrophic scars, hidradenitis suppurativa, hyperhidrosis, masseter muscle hypertrophy, and salivary gland hypertrophy, among others. A MEDLINE search from January 2000 to December 2019 was conducted on the off-label uses of botulinum toxin in dermatology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58–64.

    CAS  PubMed  Google Scholar 

  2. Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The Oxford 2011 levels of evidence. In: Oxford Centre for Evidence-Based Medicine.

  3. Wu CJ, Chang CK, Wang CY, Liao YS, Chen SG. Efficacy and safety of botulinum toxin A in axillary bromhidrosis and associated histological changes in sweat glands: a prospective randomized double-blind side-by-side comparison clinical study. Dermatol Surg. 2019;12:1605–9.

    Google Scholar 

  4. Heckmann M, Teichmann B, Pause BM, Plewig G. Amelioration of body odor after intracutaneous axillary injection of botulinum toxin A. Arch Dermatol. 2003;139(1):57–9.

    CAS  PubMed  Google Scholar 

  5. He J, Wang T, Dong J. A close positive correlation between malodor and sweating as a marker for the treatment of axillary bromhidrosis with botulinum toxin A. J Dermatol Treat. 2012;23(6):461–4.

    CAS  Google Scholar 

  6. He J, Wang T, Dong J. Effectiveness of botulinum toxin A injection for the treatment of secondary axillary bromhidrosis. J Plast Reconstr Aesthet Surg. 2017;70(11):1641–5.

    PubMed  Google Scholar 

  7. He J, Wang T, Dong J. A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis. J Dermatol Treat. 2018;29(1):102–4.

    CAS  Google Scholar 

  8. Wang T, Dong J, He J. Long-term safety and efficacy of botulinum toxin A treatment in adolescent patients with axillary bromhidrosis. Aesthetic Plast Surg. 2018;42(2):560–4.

    PubMed  Google Scholar 

  9. Lee JB, Kim BS, Kim MB, Oh CK, Jang HS, Kwon KS. A case of foul genital odor treated with botulinum toxin A. Dermatol Surg. 2004;30(9):1233–5.

    PubMed  Google Scholar 

  10. Matarasso SL. Treatment of facial chromhidrosis with botulinum toxin type A. J Am Acad Dermatol. 2005;52(1):89–91.

    PubMed  Google Scholar 

  11. Wu JM, Mamelak AJ, Nussbaum R, McElgunn PS. Botulinum toxin A in the treatment of chromhidrosis. Dermatol Surg. 2005;31(8):963–5.

    CAS  PubMed  Google Scholar 

  12. Perez Tato B, Zamora Martinez E, Sanchez Albisua B, Perez Gonzalez YC, Polimon Olabarrieta I, Marinero Escobedo S, et al. Facial and axillary apocrine chromhidrosis. Dermatol Online J. 2012;18(3):13.

    PubMed  Google Scholar 

  13. Beer K, Oakley H. Axillary chromhidrosis: report of a case, review of the literature and treatment considerations. J Cosmet Dermatol. 2010;9(4):318–20.

    PubMed  Google Scholar 

  14. Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol. 2000;143(4):824–7.

    CAS  PubMed  Google Scholar 

  15. Sanli H, Ekmekci P, Akbostanci MC. Idiopathic localized crossed (left side of the upper part of the body, right side of the lower part of the body) hyperhidrosis: successful treatment of facial area with botulinum a toxin injection. Dermatol Surg. 2004;30(4):552–4.

    PubMed  Google Scholar 

  16. George SM, Atkinson LR, Farrant PB, Shergill BS. Botulinum toxin for focal hyperhidrosis of the face. Br J Dermatol. 2014;170(1):211–3.

    CAS  PubMed  Google Scholar 

  17. Komericki P, Ardjomand N. Hyperhidrosis of face and scalp: repeated successful treatment with botulinum toxin type A. Indian J Dermatol Venereol Leprol. 2012;78(2):201–2.

    PubMed  Google Scholar 

  18. Geddoa E, Balakumar AK, Paes TRF. The successful use of botulinum toxin for the treatment of nasal hyperhidrosis. Int J Dermatol. 2008;47(10):1079–80.

    PubMed  Google Scholar 

  19. Lera M, Espana A, Idoate MA. Focal hyperhidrosis secondary to eccrine naevus successfully treated with botulinum toxin type A. Clin Exp Dermatol. 2015;40(6):640–3.

    CAS  PubMed  Google Scholar 

  20. Nygaard U, Dalager S, Spaun E, Hedelund L. Large eccrine angiomatous hamartoma: a novel clinical presentation of disease. J Dermatol Case Rep. 2015;9(3):58–61.

    PubMed  PubMed Central  Google Scholar 

  21. Jansen S, Jerowski M, Ludwig L, Fischer-Krall E, Beutner D, Grosheva M. Botulinum toxin therapy in Frey's syndrome: a retrospective study of 440 treatments in 100 patients. Clin Otolaryngol. 2017;42(2):295–300.

    CAS  PubMed  Google Scholar 

  22. Gualberto GV, Sampaio FMS, Madureira NAB. Use of botulinum toxin type A in Frey's syndrome. An Bras Dermatol. 2017;92(6):891–2.

    PubMed  PubMed Central  Google Scholar 

  23. Freni F, Gazia F, Stagno d'Alcontres F, Galletti B, Galletti F. Use of botulinum toxin in Frey's syndrome. Clin Case Rep. 2019;7(3):482–5.

    PubMed  PubMed Central  Google Scholar 

  24. Henry N, Baker BG, Iyer S. Frey's syndrome following a facial burn treated with botulinum toxin. Ann Burns Fire Disasters. 2018;31(1):47–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Bechara FG, Sand M, Achenbach RK, Sand D, Altmeyer P, Hoffmann K. Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg. 2007;33(8):924–7.

    CAS  PubMed  Google Scholar 

  26. Grazziotin TC, Buffon RB, da Silva Manzoni AP, Libis AS, Weber MB. Treatment of granulosis rubra nasi with botulinum toxin type A. Dermatol Surg. 2009;35(8):1298–9.

    CAS  PubMed  Google Scholar 

  27. Campanati A, Martina E, Giuliodori K, Bobyr I, Consales V, Offidani A. Two cases of hidradenitis suppurativa and botulinum toxin type a therapy: a novel approach for a pathology that is still difficult to manage. Dermatol Ther. 2019;32(3):12841.

    Google Scholar 

  28. Khoo AB, Burova EP. Hidradenitis suppurativa treated with clostridium botulinum toxin A. Clin Exp Dermatol. 2014;39(6):749–50.

    CAS  PubMed  Google Scholar 

  29. Shi W, Schultz S, Strouse A, Gater DR. Successful treatment of stage III hidradenitis suppurativa with botulinum toxin A. BMJ Case Rep. 2019;12(1):e226064.

    PubMed  Google Scholar 

  30. O'Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg. 2005;116(5):1575–6.

    CAS  PubMed  Google Scholar 

  31. Feito-Rodriguez M, Sendagorta-Cudos E, Herranz-Pinto P, de Lucas-Laguna R. Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A. Dermatol Surg. 2009;35(8):1300–2.

    CAS  PubMed  Google Scholar 

  32. Zanchi M, Favot F, Bizzarini M, Piai M, Donini M, Sedona P. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol. 2008;22(4):431–6.

    CAS  PubMed  Google Scholar 

  33. Saber M, Brassard D, Benohanian A. Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A. Arch Dermatol. 2011;147(5):629–30.

    PubMed  Google Scholar 

  34. Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology. 2001;57(11):2095–9.

    CAS  PubMed  Google Scholar 

  35. Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2002;28(9):822–7.

    PubMed  Google Scholar 

  36. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of dysport vs. botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149(5):1041–5.

    CAS  PubMed  Google Scholar 

  37. Campanati A, Giuliodori K, Martina E, Giuliano A, Ganzetti G, Offidani A. Onabotulinumtoxin type A (botox) versus Incobotulinumtoxin type A (xeomin) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. J Neural Transm (Vienna). 2014;121(1):21–6.

    CAS  Google Scholar 

  38. Mannava S, Mannava KA, Nazir OF, Plate JF, Smith BP, Koman LA, et al. Treatment of palmar hyperhidrosis with botulinum neurotoxin a. J Hand Surg Am. 2013;38(2):398–400.

    PubMed  Google Scholar 

  39. Kang A, Burns E, Glaser DA. Botulinum toxin A for palmar hyperhidrosis: associated pain, duration, and reasons for discontinuation of therapy. Dermatol Surg. 2015;41(2):297–8.

    CAS  PubMed  Google Scholar 

  40. Weinberg T, Solish N, Murray C. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32(4):505–15.

    CAS  PubMed  Google Scholar 

  41. Gregoriou S, Rigopoulos D, Makris M, Liakou A, Agiosofitou E, Stefanaki C, et al. Effects of botulinum toxin—a therapy for palmar hyperhidrosis in plantar sweat production. Dermatol Surg. 2010;36(4):496–8.

    CAS  PubMed  Google Scholar 

  42. Wollina U, Karamfilov T. Botulinum toxin A for palmar hyperhidrosis. J Eur Acad Dermatol Venereol. 2001;15(6):555–8.

    CAS  PubMed  Google Scholar 

  43. Lecouflet M, Leux C, Fenot M, Celerier P, Maillard H. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary palmar hyperhidrosis: a study of 28 patients. J Am Acad Dermatol. 2014;70(6):1083–7.

    CAS  PubMed  Google Scholar 

  44. Vlahovic TC, Dunn SP, Blau JC, Gauthier C. Injectable botulinum toxin as a treatment for plantar hyperhidrosis: a case study. J Am Podiatr Med Assoc. 2008;98(2):156–9.

    PubMed  Google Scholar 

  45. Campanati A, Bernardini ML, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol. 2007;17(1):52–4.

    CAS  PubMed  Google Scholar 

  46. Sevim S, Dogu O, Kaleagasi H. Botulinum toxin-A therapy for palmar and plantar hyperhidrosis. Acta Neurol Belg. 2002;102(4):167–70.

    PubMed  Google Scholar 

  47. Bernhard MK, Krause M, Syrbe S. Sweaty feet in adolescents-early use of botulinum type A toxin in juvenile plantar hyperhidrosis. Pediatr Dermatol. 2018;35(6):784–6.

    PubMed  Google Scholar 

  48. Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. 2002;47(5):667–71.

    PubMed  Google Scholar 

  49. Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. 2002;16(1):40–2.

    CAS  PubMed  Google Scholar 

  50. Kontochristopoulos G, Gregoriou S, Agiasofitou E, Nikolakis G, Rigopoulos D, Katsambas A. Regression of relapsing dyshidrotic eczema after treatment of concomitant hyperhidrosis with botulinum toxin-A. Dermatol Surg. 2007;33(10):1289–90.

    CAS  PubMed  Google Scholar 

  51. Pilkington SA, Bhome R, Welch RE, Ku F, Warden C, Harris S, et al. Bilateral versus unilateral botulinum toxin injections for chronic anal fissure: a randomised trial. Tech Coloproctol. 2018;22(7):545–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Berkel AE, Rosman C, Koop R, van Duijvendijk P, van der Palen J, Klaase JM. Isosorbide dinitrate ointment vs botulinum toxin A (dysport) as the primary treatment for chronic anal fissure: a randomized multicentre study. Colorectal Dis. 2014;16(10):360–6.

    Google Scholar 

  53. Barbeiro S, Atalaia-Martins C, Marcos P, Goncalves C, Canhoto M, Arroja B, et al. Long-term outcomes of botulinum toxin in the treatment of chronic anal fissure: 5 years of follow-up. United Eur Gastroenterol J. 2017;5(2):293–7.

    CAS  Google Scholar 

  54. Ravindran P, Chan DL, Ciampa C, George R, Punch G, White SI. High-dose versus low-dose botulinum toxin in anal fissure disease. Tech Coloproctol. 2017;21(10):803–8.

    CAS  PubMed  Google Scholar 

  55. Kavanagh GM, Tidman MJ. Botulinum A toxin and brachioradial pruritus. Br J Dermatol. 2012;166(5):1147.

    CAS  PubMed  Google Scholar 

  56. Jadhao VA, Lokhande N, Habbu SG, Sewane S, Dongare S, Goyal N. Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism. Indian J Dent Res. 2017;28(5):493–7.

    PubMed  Google Scholar 

  57. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008;26(2):126–35.

    PubMed  Google Scholar 

  58. Zhang LD, Liu Q, Zou DR, Yu LF. Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A (BTX-A) for treatment of temporomandibular disorder. Br J Oral Maxillofac Surg. 2016;54(7):736–40.

    PubMed  Google Scholar 

  59. Al-Wayli H. Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin A prospective and randomized clinical study. J Clin Exp Dent. 2017;9(1):112–7.

    Google Scholar 

  60. Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism: a double-blind, placebo-controlled study. Neurology. 2018;90(7):559–64.

    Google Scholar 

  61. Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil. 2010;89(1):16–23.

    PubMed  Google Scholar 

  62. Akhtar N, Brooks P. The use of botulinum toxin in the management of burns itching: preliminary results. Burns. 2012;38(8):1119–23.

    CAS  PubMed  Google Scholar 

  63. Naik HB, Steinberg SM, Middelton LA, Hewitt SM, Zuo RC, Linehan WM, et al. Efficacy of intralesional botulinum toxin A for treatment of painful cutaneous leiomyomas: a randomized clinical trial. JAMA Dermatol. 2015;151(10):1096–102.

    PubMed  Google Scholar 

  64. Sifaki MK, Krueger-Krasagakis S, Koutsopoulos A, Evangelou GI, Tosca AD. Botulinum toxin type A: treatment of a patient with multiple cutaneous piloleiomyomas. Dermatology. 2009;218(1):44–7.

    CAS  PubMed  Google Scholar 

  65. Onder M, Adisen E. A new indication of botulinum toxin: leiomyoma-related pain. J Am Acad Dermatol. 2009;60(2):325–8.

    PubMed  Google Scholar 

  66. Helou J, Kechichian E, El Khoury R, Tomb R. Botulinum toxin injection: a novel treatment for erosive vulvitis. Dermatol Surg. 2017;43:363–5.

    Google Scholar 

  67. Gonzalez-Ramos J, Alonso-Pacheco ML, Goiburu-Chenu B, Mayor-Ibarguren A, Herranz-Pinto P. Successful treatment of refractory pruritic Fox–Fordyce disease with botulinum toxin type A. Br J Dermatol. 2016;174(2):458–9.

    CAS  PubMed  Google Scholar 

  68. Norheim AJ, Mercer J, Musial F, de Weerd L. A new treatment for frostbite sequelae; botulinum toxin. Int J Circumpolar Health. 2017;76(1).

  69. Ravitskiy L, Heymann WR. Botulinum toxin-induced resolution of axillary granular parakeratosis. Skinmed. 2005;4(2):118–20.

    PubMed  Google Scholar 

  70. Gazerani P, Pedersen NS, Drewes AM, Arendt-Nielsen L. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol. 2009;161(4):737–45.

    CAS  PubMed  Google Scholar 

  71. Heckmann M, Heyer G, Brunner B, Plewig G. Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. J Am Acad Dermatol. 2002;46(4):617–9.

    PubMed  Google Scholar 

  72. Schuler A, Veenstra J, Ozog D. Battling neuropathic scar pain with botulinum toxin. J Drugs Dermatol. 2019;18(9):937–8.

    CAS  PubMed  Google Scholar 

  73. DePry JL, Mann M. Successful treatment of postoperative pain after mohs micrographic surgery with onabotulinum toxin A. Dermatol Surg. 2017;43(12):1491–4.

    CAS  PubMed  Google Scholar 

  74. Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857–64.

    PubMed  Google Scholar 

  75. Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med. 2010;11(12):1827–33.

    PubMed  Google Scholar 

  76. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274–83.

    PubMed  Google Scholar 

  77. Ding XD, Zhong J, Liu YP, Chen HX. Botulinum as a toxin for treating post-herpetic neuralgia. Iran J Public Health. 2017;46(5):608–11.

    PubMed  PubMed Central  Google Scholar 

  78. Sotiriou E, Apalla Z, Panagiotidou D, Ioannidis D. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol. 2009;89(2):214–5.

    PubMed  Google Scholar 

  79. Bittar JM, Ditre C. Treatment of postherpetic neuralgia with botulinum toxin type A. J Am Acad Derm. 2019;81(4):AB140.

    Google Scholar 

  80. Moon YE, Choi JH, Park HJ, Park JH, Kim JH. Ultrasound-guided nerve block with botulinum toxin type A for intractable neuropathic pain. Toxins (Basel). 2016;8(1):18.

    Google Scholar 

  81. Liu HT, Tsai SK, Kao MC, Hu JS. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. 2006;7(1):89–91.

    PubMed  Google Scholar 

  82. Li D, Xiao L. Combining botulinum toxin (A) injection with peripheral nerve stimulation in a patient for intractable ophthalmic postherpetic neuralgia. Neuromodulation. 2015;18(8):769–71.

    PubMed  Google Scholar 

  83. Jenkins SN, Neyman KM, Veledar E, Chen SC. A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon. J Am Acad Dermatol. 2013;69(5):834–5.

    PubMed  Google Scholar 

  84. Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016;43(1):56–62.

    CAS  PubMed  Google Scholar 

  85. Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma. J Hand Surg Eur. 2014;39(8):876–80.

    CAS  Google Scholar 

  86. Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. J Hand Surg Am. 2009;34(3):446–52.

    PubMed  Google Scholar 

  87. Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010;35(12):2085–92.

    PubMed  Google Scholar 

  88. Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007;119(1):217–26.

    PubMed  Google Scholar 

  89. Zhang X, Hu Y, Nie Z, Song Y, Pan Y, Liu Y, et al. Treatment of Raynaud's phenomenon with botulinum toxin type A. Neurol Sci. 2015;36(7):1225–311.

    PubMed  Google Scholar 

  90. Medina S, Gomez-Zubiaur A, Valdeolivas-Casillas N, Polo-Rodriguez I, Ruiz L, Izquierdo C, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study. Eur J Rheumatol. 2018;5(4):224–9.

    PubMed  PubMed Central  Google Scholar 

  91. Kossintseva I, Barankin B. Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. J Cutan Med Surg. 2008;12(4):189–93.

    PubMed  Google Scholar 

  92. Smith L, Polsky D, Franks AG Jr. Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol. 2012;148(4):426–8.

    CAS  PubMed  Google Scholar 

  93. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Investig. 2004;34(4):312–3.

    CAS  Google Scholar 

  94. Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017;69(8):1661–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Dhaliwal K, Griffin MF, Salinas S, Howell K, Denton CP, Butler PEM. Optimisation of botulinum toxin type A treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series. Clin Rheumatol. 2019;38(12):3669–766.

    PubMed  Google Scholar 

  96. Dhaliwal K, Griffin M, Denton CP, Butler PEM. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes. BMJ Case Rep. 2018. https://doi.org/10.1136/bcr-2017-219348.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Garrido-Rios AA, Gonzalez-Olivares M, Navarro-Vidal B, Martinez-Moran C, Borbujo J. Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin. Clin Exp Dermatol. 2018;43(4):503–5.

    CAS  PubMed  Google Scholar 

  98. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med. 2009;6(9):2523–37.

    CAS  PubMed  Google Scholar 

  99. Diomande I, Gabriel N, Kashiwagi M, Ghisu GP, Welter J, Fink D, et al. Subcutaneous botulinum toxin type A injections for provoked vestibulodynia: a randomized placebo-controlled trial and exploratory subanalysis. Arch Gynecol Obstet. 2019;299(4):993–1000.

    CAS  PubMed  Google Scholar 

  100. Hedebo Hansen T, Guldberg R, Meinert M. Botulinum toxin-treatment of localized provoked vulvodynia refractory to conventional treatment. Eur J Obstet Gynecol Reprod Biol. 2019;234:6–9.

    CAS  PubMed  Google Scholar 

  101. Jeon Y, Kim Y, Shim B, Yoon H, Park Y, Shim B, et al. A retrospective study of the management of vulvodynia. Korean J Urol. 2013;54(1):48–52.

    PubMed  PubMed Central  Google Scholar 

  102. Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res. 2007;19(1):84–7.

    CAS  PubMed  Google Scholar 

  103. Pelletier F, Parratte B, Penz S, Moreno JP, Aubin F, Humbert P. Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. Br J Dermatol. 2011;164(3):617–22.

    CAS  PubMed  Google Scholar 

  104. Tieu KD, MacGregor JL. Successful treatment of vulvodynia with botulinum toxin A. Arch Dermatol. 2011;147(2):251–2.

    PubMed  Google Scholar 

  105. Bobkiewicz A, Francuzik W, Krokowicz L, Studniarek A, Ledwosinski W, Paszkowski J, et al. Botulinum toxin injection for treatment of chronic anal fissure: is there any dose-dependent efficiency? A meta-analysis. World J Surg. 2016;40(12):3064–72.

    PubMed  PubMed Central  Google Scholar 

  106. Quintana-Castanedo L, Feito-Rodriguez M, De Lucas-Laguna R. Interdigital injection of botulinum toxin for patients with Raynaud's phenomenon. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.11.060.

    Article  PubMed  Google Scholar 

  107. Becker-Wegerich PM, Rauch L, Ruzicka T. Botulinum toxin A: successful decollete rejuvenation. Dermatol Surg. 2002;28(2):168–71.

    PubMed  Google Scholar 

  108. Thomas AJ, Larson MO, Braden S, Cannon RB, Ward PD. Effect of 3 commercially available botulinum toxin neuromodulators on facial synkinesis: a randomized clinical trial. JAMA Facial Plast Surg. 2018;20(2):141–7.

    PubMed  Google Scholar 

  109. Shinn JR, Nwabueze NN, Du L, Patel PN, Motamedi KK, Norton C, et al. Treatment patterns and outcomes in botulinum therapy for patients with facial synkinesis. JAMA Facial Plast Surg. 2019;21(3):244–51.

    PubMed  PubMed Central  Google Scholar 

  110. Kim MJ, Kim JH, Cheon HI, Hur MS, Han SH, Lee YW, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg. 2019;45(9):1155–62.

    CAS  PubMed  Google Scholar 

  111. Dayan SH, Ashourian N, Cho K. A pilot, double-blind, placebo-controlled study to assess the efficacy and safety of incobotulinumtoxinA injections in the treatment of rosacea. J Drugs Dermatol. 2017;16(6):549–54.

    CAS  PubMed  Google Scholar 

  112. Odo ME, Odo LM, Farias RV, Primavera RA, Leao L, Cuce LC, et al. Botulinum toxin for the treatment of menopausal hot flushes: a pilot study. Dermatol Surg. 2011;37(11):1579–83.

    CAS  PubMed  Google Scholar 

  113. Park KY, Kwon HJ, Kim JM, Jeong GJ, Kim BJ, Seo SJ, et al. A pilot study to evaluate the efficacy and safety of treatment with botulinum toxin in patients with recalcitrant and persistent erythematotelangiectatic rosacea. Ann Dermatol. 2018;30(6):688–93.

    CAS  Google Scholar 

  114. Eshghi G, Khezrian L, Alirezaei P. Botulinum toxin A in treatment of facial flushing. Acta Med Iran. 2016;54(7):454–7.

    PubMed  Google Scholar 

  115. Geddoa E, Matar HE, Paes TR. The use of botulinum toxin-A in the management of neck and anterior chest wall flushing: pilot study. Int J Dermatol. 2013;52(12):1547–50.

    CAS  PubMed  Google Scholar 

  116. Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015;41(Suppl 1):S9–16.

    CAS  PubMed  Google Scholar 

  117. Suh Y, Jeong GJ, Noh H, Sun S, Hwang CH, Oh TS, et al. A multicenter, randomized, open-label comparative study of prabotulinumtoxinA with two different dosages and diverse proportional injection styles for the reduction of gastrocnemius muscle hypertrophy in Asian women. Dermatol Ther. 2019;32(5):e13009.

    PubMed  Google Scholar 

  118. Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Sathaworawong A, Vanadurongwan B, Lektrakul N. A pilot study comparing the efficacy of two formulations of botulinum toxin type A for muscular calves contouring. J Cosmet Dermatol. 2018;17(6):984–90.

    PubMed  Google Scholar 

  119. Bogari M, Tan A, Xin Y, Chai G, Lin L, Min P, et al. Treatment of gastrocnemius muscle hypertrophy with botulinum toxin injection followed by magnetic resonance imaging assessment and 3-dimensional evaluation. Aesthet Surg J. 2017;37(10):1146–56.

    PubMed  Google Scholar 

  120. Xu F, Ma H, Li Y, Cai J, Gu Z-C. Individualized treatment of botulinum toxin type A for hypertrophic muscular calves with different bulging units in asian women. Dermatol Surg. 2017;43:336–43.

    Google Scholar 

  121. Lee HJ, Lee DW, Park YH, Cha MK, Kim HS, Ha SJ. Botulinum toxin a for aesthetic contouring of enlarged medial gastrocnemius muscle. Dermatol Surg. 2004;30(6):867–71.

    PubMed  Google Scholar 

  122. Han KH, Joo YH, Moon SE, Kim KH. Botulinum toxin A treatment for contouring of the lower leg. J Dermatol Treat. 2006;17(4):250–4.

    Google Scholar 

  123. Oh WJ, Kwon TR, Oh CT, Kim YS, Kim BJ. Clinical application of botulinum toxin A for calf hypertrophy followed by 3-dimensional computed tomography. Plast Reconstr Surg Glob Open. 2018;6(2):1071.

    Google Scholar 

  124. Mazzuco R, Hexsel D. Gummy smile and botulinum toxin: a new approach based on the gingival exposure area. J Am Acad Dermatol. 2010;63(6):1042–51.

    CAS  PubMed  Google Scholar 

  125. Araujo JP, Cruz J, Oliveira JX, Canto AM. Botulinum toxin type-A as an alternative treatment for gummy smile: a case report. Dermatol Online J. 2018;24(7):20.

    Google Scholar 

  126. Ghosn S, Uthman I, Dahdah M, Kibbi AG, Rubeiz N. Treatment of pachydermoperiostosis pachydermia with botulinum toxin type A. J Am Acad Dermatol. 2010;63(6):1036–41.

    CAS  PubMed  Google Scholar 

  127. Wei J, Xu H, Dong J, Li Q, Dai C. Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type A injection. Dermatol Surg. 2015;41:101–9.

    Google Scholar 

  128. Shome D, Khare S, Kapoor R. Efficacy of botulinum toxin in treating Asian Indian patients with masseter hypertrophy: a 4-year follow-up study. Plast Reconstr Surg. 2019;144(3):390–6.

    Google Scholar 

  129. Xie Y, Zhou J, Li H, Cheng C, Herrler T, Li Q. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment. Plast Reconstr Surg. 2014;134(2):209–18.

    Google Scholar 

  130. Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg. 2005;31(5):502–7 (discussion 7–8).

  131. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg. 2003;29(5):477–83 (discussion 83).

  132. Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29(5):484–9.

    PubMed  Google Scholar 

  133. Lee JH, Park JH, Lee SK, Han KH, Kim SD, Yoon CS, et al. Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. J Dermatol Treat. 2014;25(4):326–30.

    CAS  Google Scholar 

  134. Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Sathaworawong A, Lektrakul N, Manuskiatti W. The efficacy of two formulations of botulinum toxin type A for masseter reduction: a split-face comparison study. J Dermatol Treat. 2017;28(5):443–6.

    CAS  Google Scholar 

  135. Nikolis A, Enright KM, Masouri S, Bernstein S, Antoniou C. Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques. Clin Cosmet Investig Dermatol. 2018;11:347–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  136. Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010;125(6):1693–705.

    CAS  PubMed  Google Scholar 

  137. Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg. 2005;115(3):919–30.

    CAS  PubMed  Google Scholar 

  138. von Lindern JJ, Niederhagen B, Appel T, Berge S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg. 2001;107(2):327–32.

    Google Scholar 

  139. Sayed KS, Hegazy R, Gawdat HI, Abdel Hay RM, Ahmed MM, Mohammed FN et al. The efficacy of intradermal injections of botulinum toxin in the management of enlarged facial pores and seborrhea: a split face-controlled study. J Dermatol Treat. 2020:1–7.

  140. Min P, Xi W, Grassetti L, Trisliana Perdanasari A, Torresetti M, Feng S, et al. Sebum production alteration after botulinum toxin type A injections for the treatment of forehead rhytides: a prospective randomized double-blind dose-comparative clinical investigation. Aesthet Surg J. 2015;35(5):600–10.

    PubMed  Google Scholar 

  141. Rose AE, Goldberg DJ. Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg. 2013;39(3):443–8.

    CAS  PubMed  Google Scholar 

  142. Richards A, Ritz M, Donahoe S, Southwick G. Botox for contraction of pectoral muscles. Plast Reconstr Surg. 2001;108(1):270–1.

    CAS  PubMed  Google Scholar 

  143. Senior MA, Fourie LR. Botox and the management of pectoral spasm after subpectoral implant insertion. Plast Reconstr Surg. 2000;106(1):224–5.

    CAS  PubMed  Google Scholar 

  144. Bae GY, Yune YM, Seo K, Hwang SI. Botulinum toxin injection for salivary gland enlargement evaluated using computed tomographic volumetry. Dermatol Surg. 2013;39(9):1404–7.

    CAS  PubMed  Google Scholar 

  145. Scali C, Humphrey S, Jones D, Carruthers A. Treatment of posterior cheek enlargement in human immunodeficiency virus-positive individuals with botulinum toxin A. Dermatol Surg. 2013;39(9):1407–10.

    CAS  PubMed  Google Scholar 

  146. Hu L, Zou Y, Chang SJ, Qiu Y, Chen H, Gang M, et al. Effects of botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial. Plast Reconstr Surg. 2018;141(3):646–50.

    CAS  PubMed  Google Scholar 

  147. Lee SH, Min HJ, Kim YW, Cheon YW. The efficacy and safety of early postoperative botulinum toxin A injection for facial scars. Aesthetic Plast Surg. 2018;42(2):530–7.

    PubMed  Google Scholar 

  148. Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P, et al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg. 2013;66(2):209–14.

    PubMed  Google Scholar 

  149. Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81(8):1023–8.

    CAS  PubMed  Google Scholar 

  150. Huang RL, Ho CK, Tremp M, Xie Y, Li Q, Zan T. Early postoperative application of botulinum toxin type A prevents hypertrophic scarring after epicanthoplasty: a split-face, double-blind, randomized trial. Plast Reconstr Surg. 2019;144(4):835–44.

    CAS  PubMed  Google Scholar 

  151. Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair. Plast Reconstr Surg. 2014;134(3):511–6.

    CAS  PubMed  Google Scholar 

  152. Navarro-Barquín D, Lozada-Hernández E, Tejeda-Hernández M, DeLeon-Jasso G, Morales-Rescalvo F, Flores-González E, et al. Use of the type A botulinum toxin in patients submitted to cheiloplasty to improve results in scarring in patients with nonsyndromic cleft lip and palate. Eur J Plast Surg. 2019;42(3):291–4.

    Google Scholar 

  153. Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. PLoS ONE. 2014;9(12):e115690.

    PubMed  PubMed Central  Google Scholar 

  154. Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen. 2014;22(5):605–12.

    PubMed  Google Scholar 

  155. An MK, Cho EB, Park EJ, Kim KH, Kim LS, Kim KJ. Appropriate timing of early postoperative botulinum toxin type A injection for thyroidectomy scar management: a split-scar study. Plast Reconstr Surg. 2019;144(4):659–68.

    Google Scholar 

  156. Phillips TJ, Fung E, Rigby MH, Burke E, Hart RD, Trites JRB, et al. The use of botulinum toxin type A in the healing of thyroidectomy wounds: a randomized, prospective, placebo-controlled study. Plast Reconstr Surg. 2019;143(2):375–81.

    Google Scholar 

  157. Li YH, Yang J, Liu JQ, Xie ST, Zhang YJ, Zhang W, et al. A randomized, placebo-controlled, double-blind, prospective clinical trial of botulinum toxin type A in prevention of hypertrophic scar development in median sternotomy wound. Aesthetic Plast Surg. 2018;42(5):1364–9.

    PubMed  Google Scholar 

  158. Shaarawy E, Hegazy RA, Abdel Hay RM. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol. 2015;14(2):161–6.

    PubMed  Google Scholar 

  159. Pruksapong C, Yingtaweesittikul S, Burusapat C. Efficacy of botulinum toxin A in preventing recurrence keloids: double blinded randomized controlled trial study: intraindividual subject. J Med Assoc Thai. 2017;100(3):280–6.

    PubMed  Google Scholar 

  160. Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg. 2009;124(5):275–7.

    Google Scholar 

  161. Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T, Schauber J. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol. 2012;25(6):313–8.

    CAS  PubMed  Google Scholar 

  162. Robinson AJ, Khadim MF, Khan K. Keloid scars and treatment with botulinum toxin type A: the belfast experience. J Plast Reconstr Aesthet Surg. 2013;66(3):439–40.

    PubMed  Google Scholar 

  163. Uyesugi B, Lippincott B, Dave S. Treatment of a painful keloid with botulinum toxin type A. Am J Phys Med Rehabil. 2010;89(2):153–5.

    PubMed  Google Scholar 

  164. Elhefnawy AM. Assessment of intralesional injection of botulinum toxin type A injection for hypertrophic scars. Indian J Dermatol Venereol Leprol. 2016;82(3):279–83.

    PubMed  Google Scholar 

  165. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg. 2009;33(3):409–12.

    PubMed  Google Scholar 

  166. Jung GS. Temporalis muscle reduction using botulinum toxin type A for a desirable upper face circumference. Facial Plast Surg. 2019;35(5):559–60.

    CAS  PubMed  Google Scholar 

  167. Zhou R-R, Wu H-L, Zhang X-D, Ye L-L, Shao H-J, Song X-H, et al. Efficacy and safety of botulinum toxin type A injection in patients with bilateral trapezius hypertrophy. Aesthetic Plast Surg. 2018;42(6):1664–711.

    PubMed  Google Scholar 

  168. Jeong SY, Park KY, Seok J, Ko EJ, Kim TY, Kim BJ. Botulinum toxin injection for contouring shoulder. J Eur Acad Dermatol Venereol. 2017;31(1):46–7.

    Google Scholar 

  169. Austin E, Koo E, Jagdeo J. The cellular response of keloids and hypertrophic scars to botulinum toxin A: a comprehensive literature Review. Dermatol Surg. 2018;44(2):149–57.

    CAS  PubMed  Google Scholar 

  170. Yu P, Yang X, Qi Z. The use of botulinum toxin type A in the healing of thyroidectomy wounds: a randomized, prospective, placebo-controlled study. Plast Reconstr Surg. 2020;145(1):211.

    Google Scholar 

  171. Guo X, Jin X. The use of botulinum toxin type A in the healing of thyroidectomy wounds: A randomized, prospective, placebo-controlled study. Plast Reconstr Surg. 2019;144(6):1125.

    Google Scholar 

  172. Bi M, Sun P, Li D, Dong Z, Chen Z. Intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid: a systematic review and meta-analysis. Med Sci Monit. 2019;25:2950–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  173. Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126(5):246–8.

    Google Scholar 

  174. Singh S, Neema S, Vasudevan B. A pilot study to evaluate effectiveness of botulinum toxin in treatment of androgenetic alopecia in males. J Cutan Aesthet Surg. 2017;10(3):163–7.

    PubMed  PubMed Central  Google Scholar 

  175. Zhang L, Yu Q, Wang Y, Ma Y, Shi Y, Li X. A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. Dermatol Ther. 2019;32(4):12785.

    Google Scholar 

  176. Cutrer FM, Pittelkow MR. Cephalalgic alopecia areata: a syndrome of neuralgiform head pain and hair loss responsive to botulinum A toxin injection. Cephalalgia. 2006;26(6):747–51.

    CAS  PubMed  Google Scholar 

  177. Irimia P, Palma JA, Idoate MA, Espana A, Riverol M, Martinez-Vila E. Cephalalgia alopecia or nummular headache with trophic changes? A new case with prolonged follow-up. Headache. 2013;53(6):994–7.

    PubMed  Google Scholar 

  178. Tamura BM, Sortino-Rachou AM, Cuce LC. Folliculitis responds to botulinum toxin: is it possible? Dermatol Surg. 2007;33(11):1398–400.

    CAS  PubMed  Google Scholar 

  179. Hyun MY, Kim BJ, Lee C, Kim JW. Radiation-induced alopecia treated with botulinum toxin type A injection. Plast Reconstr Surg Glob Open. 2014;2(10):226.

    Google Scholar 

  180. Cutrer FM, Sandroni P, Wendelschafer-Crabb G. Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide-containing cutaneous nerves in scalp. Cephalalgia. 2010;30(8):1000–6.

    CAS  PubMed  Google Scholar 

  181. Bordelon JR, Tang N, Elston D, Niedt G, Lazic ST. Multiple apocrine hidrocystomas successfully treated with botulinum toxin A. Br J Dermatol. 2017;176(2):488–90.

    CAS  PubMed  Google Scholar 

  182. Houle MC, Al Dhaybi R, Benohanian A. Unilateral aquagenic keratoderma treated with botulinum toxin A. J Dermatol Case Rep. 2010;4(1):1–5.

    PubMed  PubMed Central  Google Scholar 

  183. Diba VC, Cormack GC, Burrows NP. Botulinum toxin is helpful in aquagenic palmoplantar keratoderma. Br J Dermatol. 2005;152(2):394–5.

    CAS  PubMed  Google Scholar 

  184. María GC, Carmen DM, Cristina MFL. Use of botulinum toxin in the treatment of aquagenic keratoderma: one case report. Dermatol Ther. 2018;31(5):e12689.

    Google Scholar 

  185. Bagazgoitia L, Perez-Carmona L, Salguero I, Harto A, Jaen P. Aquagenic keratoderma: successful treatment with botulinum toxin. Dermatol Surg. 2010;36(3):434–6.

    CAS  PubMed  Google Scholar 

  186. Kontochristopoulos G, Katsavou AN, Kalogirou O, Agelidis S, Zakopoulou N. Botulinum toxin type A: an alternative symptomatic management of Darier's disease. Dermatol Surg. 2007;33(7):882–3.

    CAS  PubMed  Google Scholar 

  187. Santiago-et-Sanchez-Mateos JL, Bea S, Fernandez M, Perez B, Harto A, Jaen P. Botulinum toxin type A for the preventive treatment of intertrigo in a patient with Darier's disease and inguinal hyperhidrosis. Dermatol Surg. 2008;34(12):1733–7.

    CAS  PubMed  Google Scholar 

  188. Ossorio-García L, Collantes-Rodríguez C, Villegas-Romero I, Linares-Barrios M. Vegetating Darier disease treated with botulinum toxin. JAMA Dermatol. 2018;154(1):106–8.

    PubMed  Google Scholar 

  189. Ebrahimi A, Radmanesh M. Botulinum toxin type-A (BT-A) for the treatment of multiple eccrine hydrocystomas. J Dermatol Treat. 2010;21(2):80–2.

    CAS  Google Scholar 

  190. Gheisari M, Hamedani B, Robati R, Mozafari N. Intralesional botulinum toxin-A injection for the treatment of multiple eccrine hidrocystomas. J Cosmet Laser Ther. 2018;20(5):287–92.

    PubMed  Google Scholar 

  191. Blugerman G, Schavelzon D, D'Angelo S. Multiple eccrine hidrocystomas: a new therapeutic option with botulinum toxin. Dermatol Surg. 2003;29(5):557–9.

    PubMed  Google Scholar 

  192. Kontochristopoulos G, Markantoni V, Stefanaki C, Kanelleas A, Rigopoulos D, Gregoriou S. Multiple eccrine hidrocystomas treated with botulinum toxin A. Clin Exp Dermatol. 2011;36(1):95–6.

    CAS  PubMed  Google Scholar 

  193. Meys R, Perrett CM. Treatment of multiple periocular eccrine hidrocystomata: is botulinum toxin or electrocautery more effective? Clin Exp Dermatol. 2015;40(1):101–3.

    CAS  PubMed  Google Scholar 

  194. Swartling C, Karlqvist M, Hymnelius K, Weis J, Vahlquist A. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol. 2010;163(5):1072–6.

    CAS  PubMed  Google Scholar 

  195. Abitbol RJ, Zhou LH. Treatment of epidermolysis bullosa simplex, Weber–Cockayne type, with botulinum toxin type A. Arch Dermatol. 2009;145(1):13–5.

    PubMed  Google Scholar 

  196. Kothapalli A, Caccetta T. Botulinum toxin type A for the first-line treatment of Hailey-–Hailey disease. Australas J Dermatol. 2019;60(1):73–4.

    PubMed  Google Scholar 

  197. Bessa GR, Grazziotin TC, Manzoni AP, Weber MB, Bonamigo RR. Hailey-Hailey disease treatment with botulinum toxin type A. An Bras Dermatol. 2010;85(5):717–22.

    PubMed  Google Scholar 

  198. Charlton OA, Stewart TJ, Rosen RH. Treatment of Hailey-Hailey disease with botulinum toxin. Australas J Dermatol. 2018;59(3):229–31.

    PubMed  Google Scholar 

  199. Lapiere JC, Hirsh A, Gordon KB, Cook B, Montalvo A. Botulinum toxin type A for the treatment of axillary Hailey–Hailey disease. Dermatol Surg. 2000;26(4):371–4.

    CAS  PubMed  Google Scholar 

  200. Ho D, Jagdeo J. Successful botulinum toxin (onabotulinumtoxinA) treatment of Hailey–Hailey disease. J Drugs Dermatol. 2015;14(1):68–70.

    PubMed  Google Scholar 

  201. Kang NG, Yoon TJ, Kim TH. Botulinum toxin type A as an effective adjuvant therapy for Hailey–Hailey disease. Dermatol Surg. 2002;28(6):543.

    PubMed  Google Scholar 

  202. Koeyers WJ, Van Der Geer S, Krekels G. Botulinum toxin type A as an adjuvant treatment modality for extensive Hailey–Hailey disease. J Dermatol Treat. 2008;19(4):251–4.

    CAS  Google Scholar 

  203. Bedi M, Taylor AL. Recalcitrant Hailey–Hailey disease responds to oral tacrolimus and botulinum toxin type A. Cutis. 2015;96(6):14–6.

    Google Scholar 

  204. Konrad H, Karamfilov T, Wollina U. Intracutaneous botulinum toxin A versus ablative therapy of Hailey–Hailey disease–a case report. J Cosmet Laser Ther. 2001;3(4):181–4.

    CAS  PubMed  Google Scholar 

  205. Legendre L, Maza A, Almalki A, Bulai-Livideanu C, Paul C, Mazereeuw-Hautier J. Botulinum toxin A: an effective treatment for linear immunoglobulin A bullous dermatosis located in the axillae. Acta Derm Venereol. 2016;96(1):122–3.

    CAS  PubMed  Google Scholar 

  206. Todberg T, Zachariae C, Bregnhoj A, Hedelund L, Bonefeld KK, Nielsen K, et al. The effect of botulinum neurotoxin A in patients with plaque psoriasis—an exploratory trial. J Eur Acad Dermatol Venereol. 2018;32(2):81–2.

    Google Scholar 

  207. Aschenbeck KA, Hordinsky MK, Kennedy WR, Wendelschafer-Crabb G, Ericson ME, Kavand S, et al. Neuromodulatory treatment of recalcitrant plaque psoriasis with onabotulinumtoxinA. J Am Acad Dermatol. 2018;79(6):1156–9.

    PubMed  Google Scholar 

  208. Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis. J Drugs Dermatol. 2014;13(11):1407–8.

    PubMed  Google Scholar 

  209. Koren A, Sprecher E, Reider E, Artzi O. A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita-associated keratoderma. Br J Dermatol. 2019.

  210. Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol. 2006;154(4):763–5.

    CAS  PubMed  Google Scholar 

  211. Gonzalez-Ramos J, Sendagorta-Cudos E, Gonzalez-Lopez G, Mayor-Ibarguren A, Feltes-Ochoa R, Herranz-Pinto P. Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatol Ther. 2016;29(1):32–6.

    PubMed  Google Scholar 

  212. Durand PD, Couto RA, Isakov R, Yoo DB, Azizzadeh B, Guyuron B, et al. Botulinum toxin and muscle atrophy: a wanted or unwanted effect. Aesthet Surg J. 2016;36(4):482–7.

    PubMed  Google Scholar 

  213. Peng HP, Peng JH. Complications of botulinum toxin injection for masseter hypertrophy: incidence rate from 2036 treatments and summary of causes and preventions. J Cosmet Dermatol. 2018;17(1):33–8.

    PubMed  Google Scholar 

  214. Kim KS, Byun YS, Kim YJ, Kim ST. Muscle weakness after repeated injection of botulinum toxin type A evaluated according to bite force measurement of human masseter muscle. Dermatol Surg. 2009;35(12):1902–6.

    CAS  PubMed  Google Scholar 

  215. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A. Am J Clin Dermatol. 2012;6(3):141–50.

    Google Scholar 

  216. Fortuna R, Vaz MA, Youssef AR, Longino D, Herzog W. Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox). J Biomech. 2011;44(1):39–44.

    PubMed  Google Scholar 

  217. Salari M, Sharma S, Jog MS. Botulinum toxin induced atrophy: an uncharted territory. Toxins (Basel). 2018;10(8):313.

    Google Scholar 

  218. Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel). 2019;11(9).

  219. Li M, Goldberger BA, Hopkins C. Fatal case of botox-related anaphylaxis? J Forensic Sci. 2005;50(1):169–72.

    PubMed  Google Scholar 

  220. Moon IJ, Chang SE, Kim SD. First case of anaphylaxis after botulinum toxin type A injection. Clin Exp Dermatol. 2017;42(7):760–2.

    CAS  PubMed  Google Scholar 

  221. Pickett A. Can botulinum toxin cause anaphylaxis after an aesthetic treatment? Clin Exp Dermatol. 2018;43(5):599–600.

    CAS  PubMed  Google Scholar 

  222. Pickett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol. 2009;61(1):149–50.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington Institute of Dermatologic Laser Surgery, 1430 K St NW, Suite 200, Washington, DC, 20005, USA

    Tina S. Alster & Iris S. Harrison

Authors
  1. Tina S. Alster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iris S. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

IH performed the literature search and drafted the manuscript. TSA critically revised the manuscript.

Corresponding author

Correspondence to Tina S. Alster.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this review.

Conflict of interest

Tina S. Alster and Iris S. Harrison have no conflicts of interest that are directly relevant to the content of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alster, T.S., Harrison, I.S. Alternative Clinical Indications of Botulinum Toxin. Am J Clin Dermatol 21, 855–880 (2020). https://doi.org/10.1007/s40257-020-00532-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-020-00532-0

Search

Navigation